Multimerization of anti-(epidermal growth factor receptor) IgG fragments induces an antitumor effect: The case for humanized 528 scFv multimers

FEBS Journal

Volumn 280, Issue 19, 2013, Pages 4816-4826

  Asano, Ryutaro ^a   Hagiwara, Yasuyo ^a   Koyama, Noriaki ^a   Masakari, Yosuke ^a   Orimo, Ryota ^a   Arai, Kyoko ^a   Ogata, Hiromi ^a   Furumoto, Shozo ^b   Umetsu, Mitsuo ^a   Kumagai, Izumi ^a  

^a TOHOKU UNIVERSITY   (Japan)

^b TOHOKU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

antitumor effect; EGFR; ScFv; ScFv multimer; Triabody

Indexed keywords

ANTINEOPLASTIC AGENT; CETUXIMAB; EPIDERMAL GROWTH FACTOR RECEPTOR; HUMANIZED EPIDERMAL GROWTH FACTOR RECEPTOR IMMUNOGLOBULIN G 528 SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY HLG0 TRIMER; HUMANIZED EPIDERMAL GROWTH FACTOR RECEPTOR IMMUNOGLOBULIN G 528 SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY HLG1 DIMER; HUMANIZED EPIDERMAL GROWTH FACTOR RECEPTOR IMMUNOGLOBULIN G 528 SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY HLG3 MONOMER; HUMANIZED EPIDERMAL GROWTH FACTOR RECEPTOR IMMUNOGLOBULIN G 528 SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY MULTIMER; PANITUMUMAB; SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; ARTICLE; BILE DUCT CARCINOMA; BINDING AFFINITY; CANCER INHIBITION; CONTROLLED STUDY; DISULFIDE BOND; DRUG DESIGN; DRUG EFFICACY; DRUG PURIFICATION; DRUG STABILITY; DRUG STRUCTURE; DRUG SYNTHESIS; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN MULTIMERIZATION; PROTEIN PHOSPHORYLATION; STRUCTURE ACTIVITY RELATION; SURFACE PLASMON RESONANCE;

BACTERIA (MICROORGANISMS);

EID: 84884588012     PISSN: 1742464X     EISSN: 17424658     Source Type: Journal    
DOI: 10.1111/febs.12451     Document Type: Article

References (39)

1. Fischer-Colbrie J, Witt A, Heinzl H, Speiser P, Czerwenka K, Sevelda P, &, Zeillinger R, (1997) EGFR and steroid receptors in ovarian carcinoma: comparison with prognostic parameters and outcome of patients. Anticancer Res 17, 613-619.
2. Nonomura A, Ohta G, Nakanuma Y, Izumi R, Mizukami Y, Matsubara F, Hayashi M, Watanabe K, &, Takayanagi N, (1988) Simultaneous detection of epidermal growth factor receptor (EGF-R), epidermal growth factor (EGF) and ras p21 in cholangiocarcinoma by an immunocytochemical method. Liver 8, 157-166.
3. Salomon DS, Brandt R, Ciardiello F, &, Normanno N, (1995) Epidermal growth factor-related peptides and their receptors in human malignancies. Crit Rev Oncol Hematol 19, 183-232.
4. Hur BU, Yoon JB, Liu LK, &, Cha SH, (2010) Isolation of a human anti-epidermal growth factor receptor Fab antibody, EG-19-11, with subnanomolar affinity from naive immunoglobulin repertoires using a hierarchical antibody library system. Immunol Lett 134, 55-61.
5. Zhou XK, Qiu J, Wang Z, Huang NY, Li XL, Li Q, Zhang YB, Zhao CJ, Luo C, Zhang NN, et al,. (2012) In vitro and in vivo anti-tumor activities of anti-EGFR single-chain variable fragment fused with recombinant gelonin toxin. J Cancer Res Clin Oncol 138, 1081-1090.
6. Carter PJ, (2006) Potent antibody therapeutics by design. Nat Rev Immunol 6, 343-357.
7. Pei XY, Holliger P, Murzin AG, &, Williams RL, (1997) The 2.0-Å resolution crystal structure of a trimeric antibody fragment with noncognate VH-VL domain pairs shows a rearrangement of VH CDR3. Proc Natl Acad Sci USA 94, 9637-9642.
8. Dolezal O, Pearce LA, Lawrence LJ, McCoy AJ, Hudson PJ, &, Kortt AA, (2000) ScFv multimers of the anti-neuraminidase antibody NC10: shortening of the linker in single-chain Fv fragment assembled in V(L) to V(H) orientation drives the formation of dimers, trimers, tetramers and higher molecular mass multimers. Protein Eng 13, 565-574.
9. Power BE, Doughty L, Shapira DR, Burns JE, Bayly AM, Caine JM, Liu Z, Scott AM, Hudson PJ, &, Kortt AA, (2003) Noncovalent scFv multimers of tumor-targeting anti-Lewis(y) hu3S193 humanized antibody. Protein Sci 12, 734-747.
10. Le Gall F, Reusch U, Moldenhauer G, Little M, &, Kipriyanov SM, (2004) Immunosuppressive properties of anti-CD3 single-chain Fv and diabody. J Immunol Methods 285, 111-127.
11. Hudson PJ, &, Kortt AA, (1999) High avidity scFv multimers; diabodies and triabodies. J Immunol Methods 231, 177-189.
12. Holliger P, &, Hudson PJ, (2005) Engineered antibody fragments and the rise of single domains. Nat Biotechnol 23, 1126-1136.
13. Asano R, Sone Y, Makabe K, Tsumoto K, Hayashi H, Katayose Y, Unno M, Kudo T, &, Kumagai I, (2006) Humanization of the bispecific epidermal growth factor receptor × CD3 diabody and its efficacy as a potential clinical reagent. Clin Cancer Res 12, 4036-4042.
14. Makabe K, Nakanishi T, Tsumoto K, Tanaka Y, Kondo H, Umetsu M, Sone Y, Asano R, &, Kumagai I, (2008) Thermodynamic consequences of mutations in vernier zone residues of a humanized anti-human epidermal growth factor receptor murine antibody, 528. J Biol Chem 283, 1156-1166.
15. Asano R, Ikoma K, Shimomura I, Taki S, Nakanishi T, Umetsu M, &, Kumagai I, (2011) Cytotoxic enhancement of a bispecific diabody by format conversion to tandem single-chain variable fragment (taFv) the case of the hEx3 diabody. J Biol Chem 286, 1812-1818.
16. Asano R, Nakayama M, Kawaguchi H, Kubota T, Nakanishi T, Umetsu M, Hayashi H, Katayose Y, Unno M, Kudo T, et al,. (2012) Construction and humanization of a functional bispecific EGFR CD16 diabody using a refolding system. FEBS J 279, 223-233.
17. Rheinnecker M, Hardt C, Ilag LL, Kufer P, Gruber R, Hoess A, Lupas A, Rottenberger C, Pluckthun A, &, Pack P, (1996) Multivalent antibody fragments with high functional affinity for a tumor-associated carbohydrate antigen. J Immunol 157, 2989-2997.
18. Willuda J, Kubetzko S, Waibel R, Schubiger PA, Zangemeister-Wittke U, &, Pluckthun A, (2001) Tumor targeting of mono-, di-, and tetravalent anti-p185(HER-2) miniantibodies multimerized by self-associating peptides. J Biol Chem 276, 14385-14392.
19. Watanabe Y, Asano R, Arai K, Shimomura I, Ogata H, Kawaguchi H, Hayashi H, Ohtsuka H, Yoshida H, Katayose Y, et al,. (2011) In vitro and in vivo antitumor effects of recombinant bispecific antibodies based on humanized anti-EGFR antibody. Oncol Rep 26, 949-955.
20. Asano R, Watanabe Y, Kawaguchi H, Fukazawa H, Nakanishi T, Umetsu M, Hayashi H, Katayose Y, Unno M, Kudo T, et al,. (2007) Highly effective recombinant format of a humanized IgG-like bispecific antibody for cancer immunotherapy with retargeting of lymphocytes to tumor cells. J Biol Chem 282, 27659-27665.
21. Asano R, Ikoma K, Sone Y, Kawaguchi H, Taki S, Hayashi H, Nakanishi T, Umetsu M, Katayose Y, Unno M, et al,. (2010) Highly enhanced cytotoxicity of a dimeric bispecific diabody, the hEx3 tetrabody. J Biol Chem 285, 20844-20849.
22. Nagorsen D, &, Baeuerle PA, (2011) Immunomodulatory therapy of cancer with T cell-engaging BiTE antibody blinatumomab. Exp Cell Res 317, 1255-1260.
23. Keating GM, (2010) Panitumumab. A review of its use in metastatic colorectal cancer. Drugs 70, 1059-1078.
24. Orita T, Tsunoda H, Yabuta N, Nakano K, Yoshino T, Hirata Y, Ohtomo T, Nezu J, Sakumoto H, Ono K, et al,. (2005) A novel therapeutic approach for thrombocytopenia by minibody agonist of the thrombopoietin receptor. Blood 105, 562-566.
25. Kikuchi Y, Uno S, Kinoshita Y, Yoshimura Y, Iida S, Wakahara Y, Tsuchiya M, Yamada-Okabe H, &, Fukushima N, (2005) Apoptosis inducing bivalent single-chain antibody fragments against CD47 showed antitumor potency for multiple myeloma. Leuk Res 29, 445-450.
26. Kortt AA, Dolezal O, Power BE, &, Hudson PJ, (2001) Dimeric and trimeric antibodies: high avidity scFvs for cancer targeting. Biomol Eng 18, 95-108.
27. Asano R, Kumagai T, Nagai K, Taki S, Shimomura I, Arai K, Ogata H, Okada M, Hayasaka F, Sanada H, et al,. (2013) Domain order of a bispecific diabody dramatically enhances its antitumor activity beyond structural format conversion: the case of the hEx3 diabody. Protein Eng Des Sel 26, 359-367.
28. Le Gall F, Kipriyanov SM, Moldenhauer G, &, Little M, (1999) Di-, tri- and tetrameric single chain Fv antibody fragments against human CD19: effect of valency on cell binding. FEBS Lett 453, 164-168.
29. Kelly MP, Lee FT, Tahtis K, Power BE, Smyth FE, Brechbiel MW, Hudson PJ, &, Scott AM, (2008) Tumor targeting by a multivalent single-chain Fv (scFv) anti-Lewis Y antibody construct. Cancer Biother Radiopharm 23, 411-423.
30. Asano R, Sone Y, Ikoma K, Hayashi H, Nakanishi T, Umetsu M, Katayose Y, Unno M, Kudo T, &, Kumagai I, (2008) Preferential heterodimerization of a bispecific diabody based on a humanized anti-EGFR antibody 528. Protein Eng Des Sel 21, 597-603.
31. Boersma YL, &, Pluckthun A, (2011) DARPins and other repeat protein scaffolds: advances in engineering and applications. Curr Opin Biotechnol 22, 849-857.
32. Lofblom J, Frejd FY, &, Stahl S, (2011) Non-immunoglobulin based protein scaffolds. Curr Opin Biotechnol 22, 843-848.
33. Binz HK, Amstutz P, Kohl A, Stumpp MT, Briand C, Forrer P, Grutter MG, &, Pluckthun A, (2004) High-affinity binders selected from designed ankyrin repeat protein libraries. Nat Biotechnol 22, 575-582.
34. Boersma YL, Chao G, Steiner D, Wittrup KD, &, Pluckthun A, (2011) Bispecific designed ankyrin repeat proteins (DARPins) targeting epidermal growth factor receptor inhibit A431 cell proliferation and receptor recycling. J Biol Chem 286, 41273-41285.
35. Bayly AM, Kortt AA, Hudson PJ, &, Power BE, (2002) Large-scale bacterial fermentation and isolation of scFv multimers using a heat-inducible bacterial expression vector. J Immunol Methods 262, 217-227.
36. Takemura S, Asano R, Tsumoto K, Arai T, Sakurai N, Kodama H, Yoshida H, Katayose Y, Suzuki M, Matsuno S, et al,. (2000) Functional Fv fragment of an antibody specific for CD28: Fv-mediated co-stimulation of T cells. FEBS Lett 476, 266-271.
37. Saijyo S, Kudo T, Suzuki M, Katayose Y, Shinoda M, Muto T, Fukuhara K, Suzuki T, &, Matsuno S, (1995) Establishment of a new extrahepatic bile duct carcinoma cell line, TFK-1. Tohoku J Exp Med 177, 61-71.
38. Fan Z, Lu Y, Wu X, &, Mendelsohn J, (1994) Antibody-induced epidermal growth factor receptor dimerization mediates inhibition of autocrine proliferation of A431 squamous carcinoma cells. J Biol Chem 269, 27595-27602.
39. Yang XD, Jia XC, Corvalan JR, Wang P, Davis CG, &, Jakobovits A, (1999) Eradication of established tumors by a fully human monoclonal antibody to the epidermal growth factor receptor without concomitant chemotherapy. Cancer Res 59, 1236-1243.